Institutional Biosafety Committee (IBC)
What is the IBC?
The Institutional Biosafety Committee (IBC) functions as the UCR review body responsible for approval and oversight of activities involving the use, storage and handling of biohazardous materials (defined below), in accordance with the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines), Medical Waste Management Act, and the CDC Biosafety in Microbiological and Biomedical Laboratories (BMBL) document. The IBC may choose to implement additional guidelines based on risk assessments.
Do I have to submit a BUA application?
A Biohazardous Use Authorization (BUA) is required for every laboratory that uses or stores biohazardous materials. The term “biohazardous materials” includes:
- Recombinant/synthetic nucleic acid molecules and genetically-modified organisms, as covered by the NIH Guidelines
- Potentially infectious organisms (typically Risk Group 2 or greater organisms) such as viruses, bacteria, fungi, or prions that can cause disease in humans or cause significant environmental or agricultural impact
- Select agents and select toxins, as covered by the CDC DSAT regulations
- Human and nonhuman primate materials (including established cell lines), as covered by the Cal/OSHA Bloodborne Pathogen Standard
- At its discretion or IACUC request, the IBC may also review protocols involving animals or animal specimens known to be reservoirs/vectors of zoonotic diseases
- Dual Use Research of Concern
Materials not within the IBC purview by regulation, that UCR may add to IBC oversight:
- Plant infectious agents or other infectious agents with potential environmental impact, exotic arthropods, exotic microorganisms, BSL-1 microorganisms, biological material requiring an APHIS, CDFA, EPA or other governmental permit
*Biological Agent Risk Group does not necessarily correspond to Biosafety Level (BSL)
What are the levels of review*?
Research at BSL2 or above requires full committee review at a convened monthly committee meeting. See deadline dates in the table below.
Research at BSL1 level requires IBC notification at initiation; however, the BUA application will require review and formal approval at a convened committee meeting. The investigator can begin work prior to IBC approval but only after completing a satisfactory EH&S pre-review. Rolling Submissions accepted.
Research consisting only of “exempt r/sNA,” human derived materials and/or agents listed in Risk Group 1 may undergo expedited review and approval, at the discretion of the Biosafety Officer and IBC Chair. These projects do not require review by the IBC at a convened meeting. Rolling Submissions accepted.
*ALL research activity, regardless of review level, is subject to a a pre-review and approval by EH&S. The pre-review includes a lab inspection, completion of relevant training, and review of the BUA application and any supplemental documents (e.g., lab-specific standard operating procedures).
Additional compliance reviews that may be required:
Institutional Animal Care and Use Committee (IACUC): The use of vertebrate animals (e.g., testing viable recombinant or synthetically modified microorganisms on whole animals) must be approved by the IACUC (via an AUP).
Institutional Review Board (IRB): IRB review of human protections may be required for some activities, such as the collection of blood or primary tissues.
Stem Cell Research Oversight (SCRO): SCRO review of the use or storage of human pluripotent stem cells is required.
Material Transfer Agreement (MTA): Some biohazardous materials (e.g., plasmids, vectors, viruses, human cell lines) cannot be obtained without a Material Transfer Agreement (MTA). The Research and Economic Development Office is required to review these contracts in accordance with UC mandated restrictions. It is recommended that you contact firstname.lastname@example.org as soon as you have determined you will be obtaining materials from an external source.
How Do I submit?
The ORI uses an online BUA submission portal for new applications or amendments. Using the online submission portal, researchers can submit their BUA to the ORI for review. Please note, the system only allows a faculty member to submit.
What are the review timelines?
The IBC meets at least once per month, every 4th Thursday of the month. In order for a BUA submission to be placed on the agenda for a meeting, the PI must submit the BUA at least 2 weeks before the scheduled meeting and have adequately addressed any issues raised during the pre-review by EH&S. If any major issues or key documents are still pending, the BUA will not be reviewed at a convened meeting. PIs are encouraged to submit renewal BUAs at least two meetings before the BUA expiration date to allow sufficient time for the pre-review and to address any issues.
BUAs are approved for a 3-year period. The IBC will contact the investigators for renewals; however, it is the responsibility of the investigator to ensure that an active approved BUA is maintained including submission of amendments when changes to the research are required.
When should I submit?
Submission Deadline Dates for BUA applications requiring full board review
(i.e., activities involving BSL2 and above work)
Submit via RED Portal by 3:00 pm
2016 – 2017
IBC Meeting Dates
|January 5, 2017
||January 26, 2017
|February 2, 2017
||February 23, 2017
|March 2, 2017
||March 23, 2017
|April 6, 2017
||April 27, 2017
|May 4, 2017
||May 25, 2017
|June 1, 2017
||June 22, 2017
|July 6, 2017
||July 27, 2017
|August 3, 2017
||August 24, 2017
|September 7, 2017
||September 28, 2017
|October 5, 2017
||October 26, 2017
Whom can I contact?
Contact Information (Making an appointment, if necessary)
Office of Research Integrity
216 University Office Building
Environmental Health & Safety (EH&S - for laboratory inspections)
UCR Biological Safety Officer
Where can I find additional information?
^ back to top